Form 4: Gilead Sciences CMO Dietmar Berger Executes Stock Vesting

Chief Medical Officer Dietmar Berger acquired 533 shares of Gilead Sciences common stock through the vesting of restricted stock units.

Summary

• Dietmar Berger, Chief Medical Officer of Gilead Sciences, Inc., reported the acquisition of 533 shares of common stock via the vesting of restricted stock units (RSUs) on June 10, 2026.
• A total of 263 shares were withheld by the company to satisfy tax obligations related to the vesting, at a price of $121.48 per share.
• Following these transactions, Berger holds 19,252 shares of Gilead Sciences common stock directly.
• The remaining unvested balance of RSUs held by the reporting person is 46,928 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding executive compensation that carries no material impact on the company's investment thesis.

Positives

• The transaction reflects the standard equity compensation vesting schedule for a senior executive, indicating alignment with long-term incentive plans.

Negatives

• The company withheld 263 shares to cover tax liabilities, which is a standard administrative procedure but reduces the net share increase for the executive.

Risks

• No specific operational or financial risks are disclosed in this ownership filing.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a disclosure of executive equity transactions.

Industry Context

StockSavvy.ai notes that this filing is a routine disclosure of executive compensation and does not signal a change in corporate strategy or market outlook for the biotechnology sector.

Comparison to Industry Standards

• The vesting schedule of 25% after one year followed by quarterly installments is consistent with standard executive compensation practices in the large-cap pharmaceutical industry.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine equity compensation event.

Next Steps

• Continued vesting of the remaining 46,928 restricted stock units according to the established 4-year schedule.

Key Dates

Keywords

Gilead Sciences, GILD, Insider Trading, Form 4, Equity Compensation, Dietmar Berger